ReviewJournal of oncology practice2019
Fallopian Tube Carcinoma.
Review in Journal of oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Fertility in the Shadow of Cancer: Experiences of Reproductive Loss Among Women with Gynecological Cancers in Ghana.PloS one · 2026Article
- Primary fallopian tube carcinoma presenting as an isolated sigmoid colon metastasis: a case report.Gynecology and pelvic medicine · 2026Article
- Serine/threonine kinase 11 (STK11) associated adnexal tumors: from biology to therapeutic impact.Human genomics · 2025Review
- Characterization of lncRNAs contributing to drug resistance in epithelial ovarian cancer.Medical oncology (Northwood, London, England) · 2025Article
- Fallopian tube carcinoma mimicking inguinal hernia: A case report with imaging and histological insights.Radiology case reports · 2025Article
- Global burden of gynaecological cancers in 2022 and projections to 2050.Journal of global health · 2024Article
- Bowel perforation with generalised peritonitis secondary to recurrent primary fallopian tube carcinoma after 17 years.BMJ case reports · 2024Article
- A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers.Frontiers in pharmacology · 2024Review
- Early-stage serous fallopian tube carcinoma.BMJ case reports · 2023Article
- Article
- CytoSaLPs score: a promising new tool for the detection and screening of extrauterine high grade serous carcinoma.BMC cancer · 2023Article
- Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.Seminars in immunopathology · 2023Review
- Clinical characterization and genomic landscape of gynecological cancers among patients attending a Chinese hospital.Frontiers in oncology · 2023Article
- 18-F fluorodeoxyglucose positron emission tomography/computed tomography findings of bilateral primary fallopian tube carcinoma and metastasis to the uterus: a case report and literature review.The Journal of international medical research · 2022Review
- Massive hypertriglyceridemia associated with paclitaxel; a case report.Gynecologic oncology reports · 2022Article
- Primary Fallopian Tube Carcinoma Presenting with a Massive Inguinal Tumor: A Case Report and Literature Review.Medicina (Kaunas, Lithuania) · 2022Review
- Primary Fallopian Tube Carcinoma: An Extremely Rare Gynecological Cancer Misdiagnosed Intraoperatively as Benign Ovarian Neoplasm: A Case Report.Clinics and practice · 2022Article
- Fallopian tube tumour presenting as supraclavicular lymph node metastasis.BMJ case reports · 2022Article
- Clinical Analysis of the Discovery of Malignant Gynecological Tumors in the Diagnosis and Treatment of Pelvic Organ Prolapse.Frontiers in surgery · 2022Article
- Fallopian tube cancer- challenging to diagnose but not as infrequent as originally thought.Journal of community hospital internal medicine perspectives · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary fallopian tube carcinoma is a rare and difficult to cure disease. It is often grouped under the epithelial ovarian cancer umbrella, together with primary ovarian and peritoneal carcinomas. More recent evidence has suggested that epithelial ovarian cancers originate from a fallopian tube precursor. The mainstay of treatment is surgical cytoreduction and platinum-based chemotherapy. There is much debate over the best timing for surgery and the best approach to delivering the chemotherapy: traditional intravenous once every 3 weeks regimen, versus intraperitoneal, versus dose-dense intravenous regimens. Although these debates continue, novel targeted therapies, including bevacizumab and poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors, have emerged. PARP inhibitors are particularly efficacious in patients with
Indexed as
Identifiers
31283415What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.